<?xml version='1.0' encoding='utf-8'?>
<document id="18038274"><sentence text="Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft."><entity charOffset="48-59" id="DDI-PubMed.18038274.s1.e0" text="Sabarubicin" /><entity charOffset="76-86" id="DDI-PubMed.18038274.s1.e1" text="cis-platin" /><entity charOffset="88-91" id="DDI-PubMed.18038274.s1.e2" text="DDP" /><pair ddi="false" e1="DDI-PubMed.18038274.s1.e0" e2="DDI-PubMed.18038274.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18038274.s1.e0" e2="DDI-PubMed.18038274.s1.e1" /><pair ddi="false" e1="DDI-PubMed.18038274.s1.e0" e2="DDI-PubMed.18038274.s1.e2" /><pair ddi="false" e1="DDI-PubMed.18038274.s1.e1" e2="DDI-PubMed.18038274.s1.e1" /><pair ddi="false" e1="DDI-PubMed.18038274.s1.e1" e2="DDI-PubMed.18038274.s1.e2" /></sentence><sentence text="Sabarubicin (MEN 10755), a new disaccaride anthracycline, has shown greater efficacy than Doxorubicin in a large panel of preclinical models and now it is in phase II clinical trials"><entity charOffset="0-11" id="DDI-PubMed.18038274.s2.e0" text="Sabarubicin" /><entity charOffset="31-56" id="DDI-PubMed.18038274.s2.e1" text="disaccaride anthracycline" /><entity charOffset="90-101" id="DDI-PubMed.18038274.s2.e2" text="Doxorubicin" /><pair ddi="false" e1="DDI-PubMed.18038274.s2.e0" e2="DDI-PubMed.18038274.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18038274.s2.e0" e2="DDI-PubMed.18038274.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18038274.s2.e0" e2="DDI-PubMed.18038274.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18038274.s2.e1" e2="DDI-PubMed.18038274.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18038274.s2.e1" e2="DDI-PubMed.18038274.s2.e2" /></sentence><sentence text=" Its promising antitumour activity promoted considerable interest to combine Sabarubicin with other antitumour agents"><entity charOffset="77-88" id="DDI-PubMed.18038274.s3.e0" text="Sabarubicin" /></sentence><sentence text=" Thus, the purpose of this study was to evaluate in vitro cytotoxic effects and in vivo antitumour activities produced by the combination of Sabarubicin and cisplatin (DDP)"><entity charOffset="141-152" id="DDI-PubMed.18038274.s4.e0" text="Sabarubicin" /><entity charOffset="157-166" id="DDI-PubMed.18038274.s4.e1" text="cisplatin" /><entity charOffset="168-171" id="DDI-PubMed.18038274.s4.e2" text="DDP" /><pair ddi="false" e1="DDI-PubMed.18038274.s4.e0" e2="DDI-PubMed.18038274.s4.e0" /><pair ddi="false" e1="DDI-PubMed.18038274.s4.e0" e2="DDI-PubMed.18038274.s4.e1" /><pair ddi="false" e1="DDI-PubMed.18038274.s4.e0" e2="DDI-PubMed.18038274.s4.e2" /><pair ddi="false" e1="DDI-PubMed.18038274.s4.e1" e2="DDI-PubMed.18038274.s4.e1" /><pair ddi="false" e1="DDI-PubMed.18038274.s4.e1" e2="DDI-PubMed.18038274.s4.e2" /></sentence><sentence text="" /><sentence text="The antitumour effect of Sabarubicin and DDP association was investigated, in vitro and in vivo, in preclinical models of lung cancer i"><entity charOffset="25-36" id="DDI-PubMed.18038274.s6.e0" text="Sabarubicin" /><entity charOffset="41-44" id="DDI-PubMed.18038274.s6.e1" text="DDP" /><pair ddi="false" e1="DDI-PubMed.18038274.s6.e0" e2="DDI-PubMed.18038274.s6.e0" /><pair ddi="false" e1="DDI-PubMed.18038274.s6.e0" e2="DDI-PubMed.18038274.s6.e1" /></sentence><sentence text="e" /><sentence text=": the non-small cell lung carcinoma (NSCLC) H460 and the small-cell lung carcinoma (SCLC) GLC4 in terms of synergism, additivity or antagonism in order to establish the best schedule for the combined treatment" /><sentence text=" Further, the correlation between antitumour activity and the pharmacokinetic parameters of the studied combination was also evaluated" /><sentence text="" /><sentence text="The drug combination in vitro was in general more cytotoxic than the single drug alone, indicating the presence of a synergistic effect in both tumour cell lines" /><sentence text=" Also, in the xenograft experiments a superior antitumoral effect was observed when Sabarubicin was combined with DDP"><entity charOffset="84-95" id="DDI-PubMed.18038274.s12.e0" text="Sabarubicin" /><entity charOffset="114-124" id="DDI-PubMed.18038274.s12.e1" text="DDP" /><pair ddi="false" e1="DDI-PubMed.18038274.s12.e0" e2="DDI-PubMed.18038274.s12.e0" /><pair ddi="false" e1="DDI-PubMed.18038274.s12.e0" e2="DDI-PubMed.18038274.s12.e1" /></sentence><sentence text=" The antitumour efficacy of Sabarubicin (6 mg/kg q4d x 5) combined with DDP (6 mg/kg q4d x 3) greatly depended on the schedule of administration"><entity charOffset="28-39" id="DDI-PubMed.18038274.s13.e0" text="Sabarubicin" /><entity charOffset="72-82" id="DDI-PubMed.18038274.s13.e1" text="DDP" /><pair ddi="false" e1="DDI-PubMed.18038274.s13.e0" e2="DDI-PubMed.18038274.s13.e0" /><pair ddi="false" e1="DDI-PubMed.18038274.s13.e0" e2="DDI-PubMed.18038274.s13.e1" /></sentence><sentence text=" In H460 tumour line, the sequential combination was more effective than the simultaneous administration of the two agents, although the antitumour efficacy was not dependent on the sequence of combination" /><sentence text=" On the other hand, a strong sequence-dependent effect was observed when Sabarubicin was combined with DDP in SCLC, GLC4"><entity charOffset="73-84" id="DDI-PubMed.18038274.s15.e0" text="Sabarubicin" /><entity charOffset="103-113" id="DDI-PubMed.18038274.s15.e1" text="DDP" /><pair ddi="false" e1="DDI-PubMed.18038274.s15.e0" e2="DDI-PubMed.18038274.s15.e0" /><pair ddi="false" e1="DDI-PubMed.18038274.s15.e0" e2="DDI-PubMed.18038274.s15.e1" /></sentence><sentence text=" In particular, the highest value of LCK = 6" /><sentence text="7 was obtained when administration of DDP followed by 24 h that of Sabarubicin"><entity charOffset="67-78" id="DDI-PubMed.18038274.s17.e0" text="Sabarubicin" /><entity charOffset="38-48" id="DDI-PubMed.18038274.s17.e1" text="DDP" /><pair ddi="false" e1="DDI-PubMed.18038274.s17.e1" e2="DDI-PubMed.18038274.s17.e1" /><pair ddi="false" e1="DDI-PubMed.18038274.s17.e1" e2="DDI-PubMed.18038274.s17.e0" /></sentence><sentence text=" Pharmacokinetics of Sabarubicin in combination with DDP was evaluated at 6 mg/kg for both drugs with different sequential schedule"><entity charOffset="21-32" id="DDI-PubMed.18038274.s18.e0" text="Sabarubicin" /><entity charOffset="53-56" id="DDI-PubMed.18038274.s18.e1" text="DDP" /><pair ddi="false" e1="DDI-PubMed.18038274.s18.e0" e2="DDI-PubMed.18038274.s18.e0" /><pair ddi="false" e1="DDI-PubMed.18038274.s18.e0" e2="DDI-PubMed.18038274.s18.e1" /></sentence><sentence text=" The experimental data showed no evidence for pharmacokinetics drug-drug interaction" /><sentence text="" /><sentence text="These preclinical results indicate the potential for a strong antitumour activity in lung tumours of the combination Sabarubicin and DDP"><entity charOffset="117-128" id="DDI-PubMed.18038274.s21.e0" text="Sabarubicin" /><entity charOffset="133-136" id="DDI-PubMed.18038274.s21.e1" text="DDP" /><pair ddi="false" e1="DDI-PubMed.18038274.s21.e0" e2="DDI-PubMed.18038274.s21.e0" /><pair ddi="false" e1="DDI-PubMed.18038274.s21.e0" e2="DDI-PubMed.18038274.s21.e1" /></sentence><sentence text=" In particular, in SCLC the best response should be given by a sequence with administration of Sabarubicin followed 24 h later by that of DDP"><entity charOffset="95-106" id="DDI-PubMed.18038274.s22.e0" text="Sabarubicin" /><entity charOffset="138-148" id="DDI-PubMed.18038274.s22.e1" text="DDP" /><pair ddi="false" e1="DDI-PubMed.18038274.s22.e0" e2="DDI-PubMed.18038274.s22.e0" /><pair ddi="false" e1="DDI-PubMed.18038274.s22.e0" e2="DDI-PubMed.18038274.s22.e1" /></sentence><sentence text=" Clinical trials based on these results are ongoing" /><sentence text="" /></document>